A new paradigm for topical generic drug products: Impact on therapeutic access - 26/02/20
Doi : 10.1016/j.jaad.2020.01.062
Sam G. Raney, PhD, Markham C. Luke, MD, PhD ⁎ 
Division of Therapeutic Performance, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland
∗Correspondence to: Markham C. Luke, MD, PhD, US Food and Drug Administration, Division of Therapeutic Performance, ORS, OGD, CDER, 10903 New Hampshire Ave, Building 75, Ste 4712, Silver Spring, MD 20993.US Food and Drug AdministrationDivision of Therapeutic PerformanceORSOGDCDER10903 New Hampshire AveBuilding 75Ste 4712Silver SpringMD20993
En prensa. Pruebas corregidas por el autor.
Disponible en línea desde el Wednesday 26 February 2020
El texto completo de este artículo está disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| The views expressed in this paper do not reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
Publicado por Elsevier Masson SAS.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?